| Contributors: |
Pastore, M. C.; Mandoli, G. E.; Giannoni, A.; Benfari, G.; Dini, F. L.; Pugliese, N. R.; Taddei, C.; Correale, M.; Brunetti, N. D.; Carluccio, E.; Mengoni, A.; Guaricci, A. I.; Piscitelli, L.; Citro, R.; Ciccarelli, M.; Novo, G.; Corrado, E.; Pasquini, A.; Loria, V.; Degiovanni, A.; Patti, G.; Santoro, C.; Moderato, L.; Malagoli, A.; Emdin, M.; Cameli, M.; Rosa, G.; Magnesa, M.; Mazzeo, P.; De Carli, G.; Bellino, M.; Iuliano, G.; Casciano, O.; Binno, S.; Canepa, M.; Tondi, S.; Cicoira, M.; Mega, S. |
| Description: |
Aims This sub-study deriving from a multicentre Italian register [Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic Registry (DISCOVER)-ARNI] investigated whether sacubitril/valsartan in addition to optimal medical therapy (OMT) could reduce the rate of implantable cardioverter-defibrillator (ICD) indications for primary prevention in heart failure with reduced ejection fraction (HFrEF) according to European guidelines indications, and its potential predictors. Methods In this observational study, consecutive patients with HFrEF eligible for sacubitril/valsartan from 13 Italian centres and results were included. Lack of follow-up or speckle tracking data represented exclusion criteria. Demographic, clinical, biochemical, and echocardiographic data were collected at baseline and after 6 months from sacubitril/valsartan initiation. Of 351 patients, 225 (64%) were ICD carriers and 126 (36%) were not ICD carriers (of whom 13 had no indication) at baseline. After 6 months of sacubitril/valsartan, among 113 non-ICD carriers despite having baseline left ventricular (LV) ejection fraction (EF) moderate, left atrial volume index (LAVi), and LV global longitudinal strain (GLS) significantly varied between the groups. With receiver operating characteristic curves, age >_ 75 years, LAVi >_ 42 mL/m2 and LV GLS >_-8.3% were associated with ICD indications persistence (area under the curve = 0.65, 0.68, 0.68, respectively). With univariate and multivariate analysis, only LV GLS emerged as significant predictor of ICD indications at follow-up in different predictive models. Conclusions Sacubitril/valsartan may provide early improvement of NYHA class and LVEF, reducing the possible number of implanted ICD for primary prevention in HFrEF. Baseline reduced LV GLS was a ... |